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Abstract
This review focuses on recent progress in understanding morphogenetic findings on the neogenesis of islet beta 
cells following Pancreatic Duct Ligation (PDL) in animal models. These results may give hope for modifications 
in the treatment of diabetes in general and transplantation in particular. On the basis of this review, translational 
studies should be developed to allow information on beta-cell neogenesis to be integrated into a potential therapy 
for Diabetes Mellitus (DM) in humans. Further studies on the development of animal models that will produce 
PDL islets for transplantation are urgently needed (Adv Clin Exp Med 2011, 20, 1, 5–14).
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Streszczenie
Praca poglądowa skupia się się na obecnym postępie w rozumieniu zmian w neogenezie komórek beta wysp 
Lagerhansa w następstwie podwiązania przewodu trzustkowego (PDL – pancreatic duct ligation) na modelu 
zwierzęcym. Uzyskane wyniki pozwalają mieć nadzieję na zmianę zasadniczego leczenia cukrzycy w przyszłości, 
a zwłaszcza zastosowanie leczenia za pomocą transplantacji. Na podstawie niniejszej pracy poglądowej można 
stwierdzić, że powinny zostać  prowadzone badania, aby pogłębić wiedzę dotyczącą neogenezy komórek beta 
w możliwej terapii cukrzycy u ludzi. Konieczne są pilne badania na modelu zwierzęcym w celu uzyskania wysp do 
przeszczepów (Adv Clin Exp Med 2011, 20, 1, 5–14). 
Słowa kluczowe: podwiązanie przewodu trzustkowego, komórki beta, neogeneza, wyspa, ekspresja genu, cukrzyca.
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The theme of the 10th Servier-IGIS Sympo-
sium, held March 26–29 2009 at St. Jean Cap Fer-
rat, France, was “A Decade of Islet Research: Im-
plications for Understanding and Treating Type 
2 Diabetes”. The proceedings of this symposium 
were recently published with a special editorial [1], 
providing the motivation for this review.
During the previous three decades, research 
on Type 2 diabetes mellitus (T2DM) was limited 
to insulin resistance and insulin action [1]. In the 
present decade, studies have highlighted the im-
portance of the correlates of the replicative capa-
bility of beta cells, beta-cell regeneration, and the 
transcription factor Pdx1 (a sine qua non factor for 
embryonic development of the pancreas and islet), 
for the development of b-cells, and b-cell function 
in post-natal life [1].
There are many studies on beta-cell neogenesis 
from rat duct epithelium during fetal life [2] and in 
the neonatal period [3]. The morphological find-
ings show that in the pancreas of a rat embryo, en-
docrine cells are initially scattered individual cells, 
but usually correlate to ducts. However, the dif-
ferentiation of progenitor cells into endocrine cells 
reflects the process of neogenesis from duct epi-
thelium, the budding of new islets from pancreatic 
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progenitor cells observed in or near ducts. Con-
vincing evidence of normal fetal pancreatic devel-
opment from rodent studies [4], as well as from a 
few human studies [5], has shown the neogenesis 
of islet cells deriving from duct or acinar cells.
Pancreatic Duct Ligation (PDL) in rats induces 
the transdifferentiation of acinar cells to insulin-
producing endocrine cells in vivo, well demon-
strated by the onset of transitional phenotypes with 
co-expression of both exocrine and endocrine cell 
markers [6]. In the PDL model of laboratory rats, 
the beta-cell mass increased two-fold in a short pe-
riod of time. Proliferation of pre-existing beta cells 
does not account for this observable rapid beta-
cell mass increase. Bouwens and Rooman [7] have 
described increased beta cells generally as a result 
of the physiological condition of high insulin de-
mand, but the absence of transient hyperglycemia 
in PDL rat models rules out a physiological reac-
tion in this model [8]. Duct cells after PDL show 
no evidence of beta-cell neogenesis from the pre-
existing ductal epithelial cells [4, 8]. Based on this 
evidence, the PDL model exhibits the production 
of new beta cells rather than their replacement [9]. 
However, transdifferentiation of acinar cells into 
beta cells in vitro has been documented [10]; this 
new evidence warrants an elucidation of the origin 
of beta cells from PDL.
Investigations of the origin of newly formed 
beta cells following PDL have to be supported by 
an evaluation of transcription factors involved in 
endocrine development. Demeterco et al. [11] sug-
gest fundamental research in beta-cell replacement 
therapy for diabetes mellitus in men in order to 
elucidate the mechanism by which endocrine dif-
ferentiation is promoted; this could be a successful 
therapeutic approach to induce endogenous beta-
cell neogenesis.
The objective of this review is to focus on recent 
progress in understanding morphogenetic findings 
on the neogenesis of islet beta cells following PDL 
in animal models. These results may give hope for 
modifications in the treatment of diabetes in gen-
eral and transplantation in particular.
The Morphology  
of the Pancreas
The human pancreas is a lobulated gland, sim-
ilar in structure to the salivary glands, though soft-
er and less compactly arranged than those organs 
(Figure 1). The human pancreas measures from 
12.5 cm to 25 cm in length and weighs between 60 
and 150 grams. The pancreas consists of the head, 
neck, tail and uncinate process. There is an acces-
sory pancreatic duct (the duct of Santorini), which 
is formed by the fusion of small ducts from the 
lower and left portion of the head of the pancreas; 
it communicates with the main duct, and drains 
the lower part of the head of the pancreas, entering 
the duodenum at the minor duodenal papilla. 
In rodents the pancreas is diffuse and the shape 
cannot be well specified. It weighs between 550 mg 
(at a body weight of 100 g) and 1 g (300 g body 
weight). In rats the pancreas is found in the cran-
iodorsal part of the abdominal cavity and can be 
divided into two parts. The first part is comprised 
of the body and right lobe; this is embedded in the 
mesoduodenum and the beginning of the mesoje-
junum. The second part, a branched flattened left 
lobe, is partially fused to the ascending colon and 
blankets the superior mesenteric-portal vein. It 
then runs along the dorsal aspect of the stomach, 
embedded in the dorsal part of the greater omen-
tum, and along the lineal artery toward the intesti-
nal surface of the spleen.
Induction of Endocrine 
Development
The pancreas develops from the fusion of 
two distinct buds, the ventral and dorsal pancre-
atic buds. These two buds emerge as evaginations 
of the embryonic gut endoderm. The main duct 
elongates; secondary ducts form, which branch 
off, elongate, and from which further ducts form 
and branch off. They develop acini at their ter-
minal ends, forming the centroacinar duct; and 
from the walls of the smaller branches, cell clumps 
bud – the presumptive islets. The islets increase 
in size through islet cell precursor proliferation 
and through the merging of cell clumps that are 
close together [12]. Serial reciprocal inductions of 
the endoderm and adjacent mesoderm determine 
the cell fate in both the ventral and dorsal bud tis-
sue types [13]. One of the first steps required for 
pancreatic development is an inductive interaction 
between the endoderm and mesoderm that directs 
a cluster of endodermal cells close to the mid-
foregut junction toward a pancreatic fate [13]. 
However, the formation and differentiation of all 
pancreatic cell types (organogenesis) continue in 
postnatal life, until three months of age.
The Microscopic Anatomy 
of the Islets of Langerhans
The islets of Langerhans are clusters of cells dis-
persed within the exocrine pancreas. The pancreas 
is composed of two structurally distinct compo-
nents in intimate association with each other. The 
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that more beta cells and alpha cells are found in 
the body, neck and tail; and PP-cells are found in 
the head [17]. In rodents, beta cells constitute ap-
proximately 60–80% of the islet cells and generally 
form the core of the islet. The surrounding layer of 
endocrine cells include alpha cells (15–20%), delta 
cells (< 10%) and PP cells (< 1%) [15, 18]. Adult 
human islets, on the other hand, are comprised of 
about 50% beta cells, 40% alpha cells, 10% delta 
cells and < 1% PP cells [15, 16, 19].
A fifth peptide hormone, namely ghrelin, pro-
duced by epsilon cells, has been identified in the 
human islet. Ghrelin-producing epsilon cells are 
thought to regulate food intake and energy bal-
ance, and to stimulate increased secretion of the 
growth hormone. However, the location of these 
cells within the endocrine compartment remains 
uncertain [20]. A number of studies have been car-
ried out to trace the origin of certain hormone-
producing cells within the islet; and common 
precursor cells that co-express the various islet 
hormones are thought to give rise to pancreatic 
endocrine cells. 
main mass (the exocrine pancreas) is a lobulated, 
branched acinar gland found throughout the organ. 
Within the exocrine pancreas, the islets of Langer-
hans constitute the endocrine pancreas responsible 
for maintaining glucose homeostasis. The islets of 
Langerhans are small spheroid clusters of cells scat-
tered throughout the organ in cell groupings with a 
combined mass of approximately 1–1.5 g, but their 
distribution is not uniform in the pancreas of all 
mammals. A recent islet study clearly distinguishes 
human islet architecture from that of rodents [14].
Immunohistochemical studies have demon-
strated that the islets of Langerhans are composed 
of four cell types designated alpha (or A or A2), 
beta (or B), delta (or D or A1), and PP (or D1 or 
F) cells, producing glucagon, insulin, somatostatin, 
and pancreatic polypeptide respectively. Although 
islet composition differs in the dorsal and ventrals 
part of the pancreas, diverging reports on the cell-
type distribution in different regions of the pan-
creas are documented. Cabrera et al. [15] reported 
a relatively even distribution in the proportion of 
endocrine cells; while Brissova et al. [16] observed 
Fig. 1. The pancreas of a human 
(above) and a rodent (below)
Ryc. 1. Trzustka człowieka 
(wyżej) i gryzonia (niżej)
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Beta-Cell Mass  
and the Pathogenesis  
of Diabetes Mellitus
A disturbance in the islet microanatomy as 
well as any disruption in the beta-cell mass balance 
may impair pancreatic islet function, leading to the 
pathogenesis of diabetes. Beta-cell mass is the total 
number of islet cells, including newly formed islet 
cells that arise from pre-existing ductal cells or other 
precursor cells (neogenesis), and islet cells formed 
by the replication (proliferation) and programmed 
cell death (apoptosis) of existing islet cells [21]. 
Beta-Cell Neogenesis  
and Apoptosis
In the pancreas, there is significant beta-cell 
neogenesis and replication during fetal life; this 
continues at a reduced rate in the neonatal stage 
of life. An increase in the apoptotic index of post-
natal beta cells has been reported in humans [22], 
pigs [23] and rodents. Newly formed beta cells take 
about 30–40 days to reach their mature and fully 
functional potential [24]. 
Beta-Cell Pathogenesis  
and the Etiology  
of Diabetes Mellitus
The significance of the beta-cell mass in the 
pathophysiology of the pancreas has been the focus 
of extensive research [25]. The mass of beta cells is 
an important tool for the regulatory mechanisms 
where changes can result in a partial or complete 
deficiency in insulin secretion. However, changes 
in beta-cell function and insulin synthesis are a 
direct consequence of the balance between the de-
generation and proliferation of these cells, which 
are critical for the pathophysiology of the pancre-
as. Beta-cell mass loss in the pancreas results from 
an autoimmune disorder induced by T-cells that 
destroy beta cells and impair insulin production, 
thereby suppressing the signaling responses that 
trigger cellular uptake of glucose and glucose me-
tabolism in cells. This situation leads to type 1 dia-
betes, also known as Insulin Dependent Diabetes 
Mellitus (IDDM). An increase in beta-cell mass, 
on the other hand, could be a response to insulin 
resistance in body tissues, whereby insulin may be 
present but a lack of insulin-stimulation signaling 
the proper cellular uptake of glucose leads to a de-
crease in glucose metabolism: a typical case of type 
2 diabetes, also known as Non-Insulin Dependent 
Diabetes Mellitus (NIDDM).
The Pancreatic Duct 
Ligation Procedure
Ligation of the pancreatic duct (PDL) has been 
an experimental procedure for many years; it was 
initially aimed at treating a disease – i.e., pancrea-
titis – but a common opinion emerged that PDL 
induced a considerable level of pancreatic atrophy. 
This opinion corroborated a study by a prominent 
19th-century researcher, Frederick Banting, who 
made the same observation while trying to isolate 
a pancreatic secretion using the duct ligation pro-
cedure. Despite the fact that many authors of that 
time observed atrophy of the pancreas following 
duct ligation, there was serious controversy as to 
the reason for or the origin of a remarkable in-
crease in mass of the surviving islet [4, 8].
Subsequent studies on the pancreas have re-
vealed that transcription factors may be involved 
in the proliferation of the islet cells after Pancre-
atic Duct Ligation [4]. Page et al. [26] reported a 
similarity between the formation of normal fetal 
pancreas tissue and that of newly-formed beta 
cells following PDL; this is thought to be due to the 
plausible stem cell capacity of the adult pancreas. 
Also, atrophy of the pancreatic cells following duct 
ligation was noted as a direct consequence of aci-
nar cell death, which triggered islet proliferation 
and neogenesis from duct-like epithelial cells [27].
A recent study on the cell lineage in a duct-
ligated pancreas revealed that an increase in beta-
cell mass does not have any contribution from pre-
existing ductal epithelial cells. Insulin-producing 
beta cells develop from pancreatic exocrine duct 
cells only during embryogenesis, not during post-
natal life [4]. This conflicting evidence warrants an 
assessment of other lineage-selective transcription 
factors for endocrine development in PDL tissues.
Transcription Factors 
Involved in Endocrine 
Development
Transcription factors are involved both in de-
termining early cellular development and in the 
differentiation of progenitor cells, and later in 
maintaining the pancreatic cell phenotype. Several 
of these factors have been implicated in pancreas 
development [28], during which they are recog-
nized to be critical regulators of gene expression 
[29]. These include transcription factors of the 
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homeodomain family (Pdx1, Hb9, Pbx1, HNF1β, 
HNF6, Pax4, Pax6, Nkx2.2, Nkx6.1, Isl1, HNF1∝, 
HNF4∝, and Brn4) [4], the basic helix-loop-helix 
(bHLH) family (Ngn3, Beta2/NeuroD, Hes1, p48) 
and the forkhead/winged helix family (Foxa2/
HNF3β, Foxa1/HNF3∝).
A number of homeodomain factors, such as 
Pdx1, Pax4, Pax6, Nkx2.2 and Nkx6.1, and an addi-
tional bHLH transcription factor, such as NeuroD, 
are necessary for the differentiation and mainte-
nance of mature and differentiated cells. Although 
bHLH transcription factor Ngn3 is both necessary 
and sufficient for driving undifferentiated pro-
genitor cells to an endocrine fate, Ngn3 expres-
sion ceases before islet cells are fully differentiated. 
However, Pdx1 expression in mature differenti-
ated cells is specific to insulin-secreting cells.
Pancreatic Duodenal 
Homeobox Gene-1
The pancreatic duodenal homeobox gene-1 
(Pdx1) is a homeodomain transcription factor 
with a key regulatory function both in pancreas de-
velopment and in the differentiation of progenitor 
cells to become adult beta cells. It is also called the 
insulin promoter factor-1 (Ipf1), islet duodenum 
homeobox-1 (IDX-1), somatostatin transactivating 
factor-1 (STF-1) or glucose sensitive factor (GSF). 
Pdx1 belongs to a “ParaHox” gene cluster expressed 
in the lateral endoderm domain at somites 7 to 9 in 
the vertebrate axis that contributes to the develop-
ment of the pancreas. It is a pancreas specific ho-
meoprotein. Because of this, it has been found to be 
a beta- and gamma-cell-specific regulatory factor 
for the expression of the insulin and somatostatin 
genes. The pancreatic duodenal homeobox gene-1 
also regulates the expression of other islet-specific 
genes like Glut-2, islet amyloid polypeptide and 
glucokinase. In the developing pancreas, Pdx1 is 
first detected at e8.5 in the ventral gut endoderm 
in cells that later form the ventral pancreatic bud. 
At e9.5 Pdx1 is expressed in both the ventral and 
dorsal pancreatic buds. From e11.5 to e13.5, Pdx1 
expression is seen throughout the developing pan-
creatic epithelium. But when the exocrine pancreas 
begins to form (e14-e15), the islets mature into 
hormone-producing cells and Pdx1 expression 
becomes restricted to the endocrine compartment 
(e16.5-e18.5) and dispersed endocrine cells of the 
duodenal wall. Later, in the adult pancreas, Pdx1 
acts as a master regulator of insulin gene expres-
sion. Subpopulations of somatostatin-producing 
and pancreatic polypeptide-producing cells also 
express Pdx1, but Pdx1 expression is seen only in a 
few glucagon-producing cells.
Targeted disruption of the Pdx1 gene and ho-
mozygous Ipf1 mutations result in agenesis of the 
pancreas [30]. Null mutation Pdx1 mice are vi-
able, but pancreatic development is arrested at a 
very early stage and the animals die within days 
after birth. In early pancreas development, a few 
insulin-expressing cells are detected in Pdx1 null 
mice, suggesting that a population of insulin-posi-
tive, Pdx1-negative cells arises separately from the 
mature Pdx1-expressing beta cells of the developed 
pancreas. However, as Stoffers et al. pointed out, 
“the expression of Pdx1 in the gut endoderm is 
essential for the pancreatic program to continue 
and all pancreatic tissues subsequently differenti-
ate from Pdx1-positive precursors” found in this 
germ tissue [31]. It has been noted that a child that 
was homozygous for an inactivating mutation in 
Pdx1 was born without a pancreas, which empha-
sizes the significance of the Pdx1 transcription fac-
tor in the development of the mouse as well as the 
human pancreas [30, 32].
The rat, mouse and human Pdx1 genes are lo-
calized respectively on chromosomes 12, 5 and 13. 
The coding region of the Pdx1 gene has two exons; 
the first encodes for the NH2-terminal region of the 
gene, and the second encodes for the homeodo-
main and COOH-terminal domain. The activa-
tion of Pdx1 is contained within the NH2-terminal 
region, however its homeodomain is involved in 
DNA binding; both the NH2-terminal region and 
the homeodomain are involved in protein-protein 
interactions [33].
Neurogenin3
Neurogenin3 (Ngn3) is a proendocrine fac-
tor belonging to the basic helix-loop-helix family 
(bHLH). Neurogenin3 is considered a marker of 
islet precursor cells, and has been shown to be es-
sential for the development of all endocrine cell 
lineages of the pancreas [34]. Pancreatic endocrine 
cells develop from the precursor cells expressing 
Pdx1 and the bHLH-family transcription factor 
Ngn3. In mice, Ngn3 expression is first observed 
at e9.5, and the number of Ngn3-expressing cells 
increases until e15.5 – exactly when islet cell dif-
ferentiation is at its peak – and diminishes greatly 
thereafter with little or no detection of Ngn3 in 
the adult pancreas. Co-expression of Ngn3 with 
islet hormones (insulin, glucagon, somatostatin, 
pancreatic polypeptide) cannot be detected at this 
adult stage, although all four-islet cell types de-
velop from Ngn3-expressing cells that are found 
adjacent to ductal cells.
In Ngn3-deficient mice, all islet cell types are 
absent in every stage of development, but exocrine 
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tissues and ductal tissues develop normally [34]. 
It is evident that Ngn3 expression is a functional 
marker of an islet cell precursor population in the 
developing pancreas. Since Ngn3 is both sufficient 
and necessary to initiate the differentiation of is-
let cells during development, it may be concluded 
that the endocrine fate of cells is strictly controlled 
by the activity of specific transcription factors that 
regulate the cis-acting elements within the pro-
moter region of the Ngn3 gene [34]. Hepatocyte 
nuclear factor 6 (HNF6), HNF3β / FOXA2 and 
HNF1∝ bind to the Ngn3 promoter, acting as its 
activators; while Ngn3 acts as an upstream regula-
tor for the transcription factors Pax6, Pax4, Beta2/
NeuroD, Nkx6.1, Nkx2.2 and Isl1, and simultane-
ously represses its own promoter [35].
Mice homozygous for a null HNF1∝ gene have 
smaller islets and secrete little insulin. Mice em-
bryos lacking HNF6 expression present a signifi-
cant reduction in endocrine differentiation, with 
critically reduced levels of Ngn3 expression [36]. 
A lack of foregut formation is observed in FOXA2 
/ HNF3β null mice as well. Expression of the HNF 
factors is therefore considered to be involved in a 
cooperative mechanism in the cell-type-restricted 
activation of Ngn3 expression, but is not sufficient 
for Ngn3 expression [37].
Neurogenin3 promoters have binding sites 
for HES1, which is a transcriptional repressor of 
bHLH genes; it is therefore believed to inhibit 
Ngn3 expression through the Notch signaling 
pathway. Over-expression of Ngn3 and an absence 
of HES1 show a similar pancreatic phenotype. Lat-
eral inhibition of Ngn3 expression via the Notch-
pathway is essential for the expansion of epithelial 
cells before differentiation. However, premature 
over-expression of Ngn3 blocks the Notch-path-
way, which leads to a poorly branched ductal epi-
thelium, blockage of exocrine development and ac-
celeration of islet cell differentiation. The evidence 
therefore suggests that the Notch signalling path-
way contributes to regulating the balance between 
progenitor cell differentiation and proliferation 
during pancreas development [38, 39].
Human Neurogenic  
Helix-Loop-Helix Protein 
Gene
The Human neurogenic helix-loop-helix protein 
gene (NeuroD/Beta2), which is a bHLH factor and 
an important activator of insulin gene transcription, 
is also required in order to generate a normal mass 
of pancreatic beta cells and alpha cells. The activa-
tion of NeuroD expression in cells that co-express 
Ngn3 and Pdx1 is a very early step in pancreatic 
endocrine differentiation. NeuroD is activated by 
Ngn3, although these two factors are expressed in 
different cells. It has been established that NeuroD-
positive cells arise from cells that express Ngn3. 
NeuroD expression is detected at e9.5, co-localizing 
with early glucagon-expressing cells [40]. 
Null mice for the NeuroD gene die three to 
five days after birth due to severe hyperglycemia; 
the islets’ beta cell count is reduced by 75%, and 
alpha and delta cells are also reduced and irregular 
in shape. The Notch pathway antagonizes NeuroD 
and bHLH proteins Ngn3. As Jensen et al. wrote: 
“Activation of Notch receptors leads to activation 
of Hairy and Enhancer-of-split (HES) type pro-
teins, which in turn act as transcriptional repres-
sors of bHLH genes. Mice lacking Notch ligand 
Delta like-1 (Dll1) or the DNA-binding protein 
RBP-jk (activator of HES1), have accelerated dif-
ferentiation of pancreatic endocrine cells and sub-
sequently severe pancreatic hypoplasia due to pre-
mature differentiation of pancreatic stem cells into 
endocrine cells” [40].
Paired Box Gene 6
Paired box gene 6 (Pax6) belongs to the Pax mul-
tigene family of transcription factors that contribute 
to the regulation of pancreatic endocrine cell differ-
entiation [41]. Pax6 expression is mainly detected 
in the eye, the central nervous system, the nose and 
the endocrine pancreas. Sharing a similar structure 
with Pax4 in their corresponding homeodomain 
[42], Pax6 is also expressed in both the ventral and 
dorsal developing pancreas; but its expression is de-
tected as early as e9.5 in the mouse, and continues 
throughout the development of the pancreas until 
the endocrine cells are fully formed [42].
A mouse lacking the Pax6 gene does not sur-
vive after birth; the pancreas of such a mutant con-
tains very few fully differentiated beta cells, delta 
cells and PP cells within a malformed islet. Alpha 
cells are completely absent in this pancreas, but 
the development of the exocrine cells tends to be 
normal. Mice that lack both Pax4 and Pax6 do not 
develop any endocrine cells; these findings suggest 
that both Pax4 and Pax6 are necessary for the reg-
ulation of the final steps in pancreatic endocrine 
cell differentiation [42].
Clinical Implications
Advances in research in recent years have shed 
considerable light on how transcription factors 
regulate endocrine pancreas development [43]. 
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Although recent evidence has shown that newly 
formed beta cells following PDL do not originate 
from the pre-existing ductal epithelium [4], the cel-
lular mechanisms involved in the recapitulation of 
these newly formed beta cells remain unknown.
For these reasons, the future of a potential thera-
py for Diabetes Mellitus (DM) lies in understanding 
the morphogenetics of islet cell neogenesis, which 
remains the ultimate hope for modifications in the 
treatment of diabetes in general and transplantation 
in particular. The first attempt at islet transplanta-
tion was made in 1893, when sheep pancreatic ex-
tracts were transplanted into a young patient, who 
showed improvement for only 24 hours. After the 
discovery of insulin by Banting and Best in 1921, in-
sulin remained the only treatment for diabetes until 
Ballinger and Lacy successfully treated a diabetic 
rat by transplanting islet isografts. Although many 
other subsequent transplants followed in 1970s and 
1980s in rats and in humans, there were numerous 
setbacks related to the use of immunosuppressants. 
A breakthrough came in 2000, when Shapiro report-
ed a 100% success rate in seven human transplants. 
Despite remarkable progress, the overall world suc-
cess rate in treating diabetes by islet transplantation 
remains very low – just 10%, which is certainly due 
to such challenges as insufficient donor organs, the 
necessity of using immunosuppressants [44] and 
the technical/clinical bias during the transplantation 
process, which requires more collaboration between 
researchers. It is therefore relevant to explore other 
avenues for the self-generation of beta cells within 
the organ itself, which could be a way to overcome 
the challenges of Insulin Dependent DM.
The transplantation of whole pancreases has 
improved the lives of large numbers of diabetic 
patients in the developed world, but the burden 
of immunosuppressive agents still impacts on the 
quality of life. The transplantation of allogeneic 
fetal tissue is a proven alternative, [44] although 
it is also impacted upon by immunosuppressive 
agents. The transplantation of adult or fetal islets 
of Langerhans is a promising therapeutic option 
for the treatment of DM, but the low availability 
Fig. 2. Diagram showing the proposed source of beta cells in the PDL model
Ryc. 2. Proponowane źródło komórek beta w modelu PDL
Fig. 3. Diagram showing time-related gene expression in post PDL tissue 
Ryc. 3. Ekspresja genu w czasie w tkance po PDL
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of human donor pancreases and the lack of suit-
able donor tissue remain a major obstacle. Duct-
ligated pancreas transplantation has been shown 
to have the same efficacy as foetal tissue [26, 27]; 
and as the model involved the transplantation of 
syngeneic tissue, immunosuppressive agents were 
unnecessary. However, the lineage of endocrine 
cell development in the PDL model is poorly un-
derstood, and is one of the questions that this the-
sis attempts to answer. Pancreatic stem cells resid-
ing within the ductal epithelium have been used 
to generate islet-like clusters in vitro, which has 
partially reverted DM in animal models. Hence, 
understanding the processes of the cellular mech-
anism in the lineage of endocrine cells in duct liga-
tion-induced neogenesis will be a valuable tool in 
improving beta-cell replacement in patients with 
diabetes, thereby alleviating the burden of Diabe-
tes Mellitus. 
In studies presented at the first annual meet-
ing of the Islet Society [45] and at the WSU In-
ternational Research Conference [46], the authors 
suggested that the newly formed beta cells derived 
from centroacinar cells; and that there is a possible 
cell-to-cell interaction between pre-existing mes-
enchymal cells and pre-existing islet cells, which 
might induce the “facultative stem cell” capacity 
of the pre-existing beta cells (Fig. 2), as suggested 
by Michalopoulos in the case of the liver [47]. Fig-
ure 3 presents a diagram of the time-related gene 
expression in a PDL pancreas, which would help 
identify the phenomena involved in the lineages of 
beta cells in the PDL model; while Fig. 4 summa-
rizes the ongoing cellular changes related to our 
observation. The combination of mesenchymal 
cells with the pre-existing beta cells in the PDL 
pancreas warrants future investigation.
Conclusions
On the basis of this review, translational stud-
ies should be developed to allow information on 
beta-cell neogenesis to be integrated into a po-
tential therapy for Diabetes Mellitus in humans. 
Further studies on the development of an animal 
model that will produce PDL islets for transplanta-
tion are urgently needed. 
Fig. 4. Representative photomicrographs showing ongoing changes in the PDL tissue (H&E, ×20): A) at 6–24 h post 
PDL: granulated cells (arrow), basement membrane (arrow head); B) at 36–60 h post PDL: clump of acinar cells 
(arrow) with infiltrated macrophages (arrow heads); C) at 72 h post PDL: acinar deletion (star) and infiltrated macro-
phages (arrow); D) at 84-120 h post PDL: remodelled acini and islet
Ryc. 4. Typowe zmiany zachodzące w tkance po PDL (H&E, 20×)
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